CRISPR Therapeutics Pivots to Cardiovascular and Autoimmune Focus with Five Key Data Readouts Expected in 2H26
Goldman Sachs 47th Annual Global Healthcare Conference, June 9, 2026
CRISPR Therapeutics is entering a defining period as it transitions from a single-product company toward a diversified clinical-stage biotech, with CFO Raju Prasad outlining plans for five clinical trial readouts across three distinct programs in the back half of 2026. The company is making a deliberate strategic shift away from broad-based oncology development toward cardiovascular and autoimmune indications, where Prasad believes the company can capture meaningful value with more manageable clinical development programs and faster paths to approval.
Speaking at the Goldman Sachs Healthcare Conference, Prasad emphasized that the upcoming data will not only validate the company's pipeline but also inform multiple pivotal trial initiations planned for 2027. With over $2.4 billion in cash on the balance sheet following an opportunistic fundraise earlier this year, CRISPR is positioning itself to advance multiple assets through pivotal development without immediate financing constraints.
Allogeneic CAR-T Strategy Shifts Toward Autoimmune Indications
The most significant strategic revelation from the conference concerned CRISPR's allogeneic CAR-T platform, where the company appears to be deprioritizing oncology in favor of autoimmune disease development. Prasad candidly acknowledged that while the allogeneic cell therapy field began with an oncology focus, the value creation opportunity now looks substantially more attractive in autoimmune applications.
The rationale is straightforward: clinical trial economics. "On the autoimmune side of development, the autologous players are getting relatively sizable trials, saying that 25 to 50 to 75 patients single-arm trial sample size for approval," Prasad explained. "On the oncology side, I think the trials are much more sizable, 250, 300 patient trials." For a company of CRISPR's scale, the return on investment from running large oncology pivotal trials appears increasingly unattractive compared to bundling multiple autoimmune indications for similar development costs.
CRISPR's zugo-cel program has now dosed over 14 patients across multiple autoimmune indications, with the first two systemic lupus erythematosus patients remaining in durable long-term remission through 12 months and 9 months respectively. The second half data update will include over 20 patients across a basket trial encompassing lupus, scleroderma, and myositis. Prasad noted that the company aims to demonstrate it can recapitulate the impressive autologous CAR-T profile seen in autoimmune disease, where patients have remained in remission for four to five years following treatment.
The cost structure for zugo-cel is particularly compelling. At the dose levels that have achieved remissions, CRISPR expects cost of goods to be $10,000 or less, creating what Prasad characterized as "a low cost of goods, high-margin product profile, even at a reasonable price point" in the autoimmune setting. The company is also exploring CNS autoimmune indications where it believes allogeneic CAR-T may have advantages over T-cell engagers or in vivo CAR-T approaches due to superior blood-brain barrier penetration.
Cardiovascular Portfolio Positions for Multiple Pivotal Decisions
CRISPR's cardiovascular franchise represents the other major pillar of its strategic repositioning, with two programs advancing toward pivotal development. The CTX310 program targeting ANGPTL3 for cardiovascular disease will provide Phase Ia follow-up data and Phase Ib indication-specific data in the second half. The company appears to be homing in on severe hypertriglyceridemia as its lead indication, where Prasad believes CRISPR can differentiate from APOC3-targeted RNA therapies.
The strategic logic centers on addressing what appear to be liabilities of the APOC3 approach. "We did see an increase in hepatic fraction as well as an increase in LDL in the patients" with the Arrowhead APOC3 program, Prasad noted. "What we know from the ANGPTL3 target is that we do get a significant reduction in LDL. In our Phase I, it was about 50% across the basket study." CRISPR has also observed reductions in hepatic fat fraction with ANGPTL3 inhibition, potentially offering a cleaner metabolic profile than competitive approaches. Combined with the one-time treatment proposition versus chronic RNA therapy administration, CRISPR sees a path to differentiation despite multiple players in the hypertriglyceridemia space.
The company achieved approximately 80 percent ANGPTL3 reduction at its DL4 dose in the Phase Ia study, which it believes correlates to complete hepatic ANGPTL3 knockdown. If CRISPR can demonstrate triglyceride reductions in the high 50 percent to low 70 percent range seen with RNA therapies in severe hypertriglyceridemia, combined with favorable LDL and hepatic fat effects, the one-time treatment paradigm could resonate with both physicians and payers.
The refractory hypertension program targeting angiotensinogen represents what Prasad called "probably the biggest disconnect between PI enthusiasm and investor enthusiasm." The company believes making patients normotensive with a one-time gene editing intervention, particularly in the refractory population on five therapies plus a diuretic, could fundamentally change treatment paradigms. The program remains on track for Phase I initiation in 2026.
Factor XI Program Enters Critical Validation Period
The partnered CTX611 Factor XI siRNA program with Sirius Therapeutics is entering a decisive phase, with Phase II data from a total knee arthroplasty study expected in the second half alongside multiple competitive readouts that will define the indication landscape. CRISPR is testing three dose levels against enoxaparin in a standard trial design, looking to demonstrate single-digit thromboembolic rates versus the low double-digit rates typically seen with enoxaparin.
The market opportunity expands dramatically depending on which indications get validated. Prasad outlined three value tiers: cancer-associated thrombosis represents a "low-hanging fruit, high-probability success" worth approximately $1 billion; the DOAC-ineligible atrial fibrillation population of 2 million patients represents a $5 billion opportunity; and if the milvexian trial successfully derisk the full atrial fibrillation market of 8 million patients, the opportunity expands to $15 billion to $20 billion.
Critically, most of this will be derisked by external data before CRISPR needs to commit to pivotal development in 2027. The Bayer asundexian program recently hit a secondary stroke prevention trial, providing some validation of Factor XI in arterial indications. The upcoming milvexian data in atrial fibrillation against DOACs and the abelacimab data in DOAC-ineligible patients expected early next year will largely define the commercial landscape before CRISPR makes its indication selection decisions.
The company is also running a multiple-dose trial evaluating once every three months versus once every six months dosing regimens. The partnership with Sirius includes options for two additional siRNA candidates, which Prasad indicated would align with CRISPR's cardiometabolic and autoimmune therapeutic area focus.
Next-Generation Programs and Platform Expansion
CRISPR is developing CTX321, a next-generation Lp(a) program with what it believes is a more potent guide RNA capable of achieving greater Lp(a) reduction than its first-generation approach. The entire development thesis hinges on the Novartis HORIZON trial readout expected in the second half of 2026, which will validate or invalidate Lp(a) as a meaningful biomarker for atherosclerotic cardiovascular disease. Prasad emphasized the company needs to see the high threshold cohort at 90 mg/dL achieve statistical significance to justify continued investment.
If HORIZON succeeds, the genetic basis of elevated Lp(a) and the lifetime nature of the condition make it a natural fit for one-time gene editing intervention. Patients know their Lp(a) levels from an early age and face decades of chronic therapy if RNA approaches become standard of care, creating the adoption dynamic CRISPR has seen in other settings.
The alpha-1 antitrypsin deficiency program CTX460 remains on track for mid-2026 Phase I initiation. CRISPR is using its synthase editing technology, which it believes is more efficient and potent than competitive approaches, aiming for 18 to 20 micromolar AATD production to achieve normalization. The company is leveraging the lipid nanoparticle formulation developed for its cardiovascular programs, giving it confidence in the therapeutic window.
On in vivo CAR-T, CRISPR is pursuing both transient mRNA and nonviral integrating CAR approaches. Prasad believes the company's integrated capabilities in LNP, mRNA, and manufacturing at scale position it to develop a best-in-class profile that hasn't yet emerged in the field. "We don't think that profile has been fully generated yet," he noted. "And so we have the ability to catch up and create a best-in-class profile there."
Capital Allocation and Partnership Strategy
CRISPR's $2.44 billion cash position following its early 2026 fundraise gives it substantial optionality around asset development and business development. Prasad emphasized the company wanted to avoid being in a position where partnership decisions were driven solely by capital constraints rather than strategic logic. "We never want to be in a position where we have to make a decision on any of our assets based solely on resource allocation," he said.
That said, the company remains open to partnerships where the indication opportunity or development requirements exceed what makes sense for a company of CRISPR's scale. If Factor XI development expands to the full atrial fibrillation market following positive milvexian data, Prasad acknowledged "there's probably several pharma companies that would be interested." Similarly, broad-based cardiovascular development across multiple indications including potential cardiovascular outcomes trials might warrant a strategic partner.
The allogeneic CAR-T opportunity in autoimmune disease, by contrast, appears more appropriately sized for CRISPR to advance independently. The company characterized this as "bite size that we can take" given the smaller trial sizes and ability to bundle multiple indications efficiently.
Prasad positioned the next 12 to 18 months as a critical growth phase where CRISPR will emerge with clarity on its second and third programs, path to profitability, and trajectory toward what he characterized as the $10 billion to $15 billion market capitalization that "really defines a leader in biotech and not just a gene editing leader." With commercial revenue from CASGEVY through the Vertex partnership, multiple pivotal programs starting in 2027, and substantial cash reserves, the company projects reaching profitability as a question of when rather than if.